These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 34544752)

  • 1. INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors.
    Li Q; Jiang B; Guo J; Shao H; Del Priore IS; Chang Q; Kudo R; Li Z; Razavi P; Liu B; Boghossian AS; Rees MG; Ronan MM; Roth JA; Donovan KA; Palafox M; Reis-Filho JS; de Stanchina E; Fischer ES; Rosen N; Serra V; Koff A; Chodera JD; Gray NS; Chandarlapaty S
    Cancer Discov; 2022 Feb; 12(2):356-371. PubMed ID: 34544752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.
    Li Z; Razavi P; Li Q; Toy W; Liu B; Ping C; Hsieh W; Sanchez-Vega F; Brown DN; Da Cruz Paula AF; Morris L; Selenica P; Eichenberger E; Shen R; Schultz N; Rosen N; Scaltriti M; Brogi E; Baselga J; Reis-Filho JS; Chandarlapaty S
    Cancer Cell; 2018 Dec; 34(6):893-905.e8. PubMed ID: 30537512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
    Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
    Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment.
    Glaviano A; Wander SA; Baird RD; Yap KC; Lam HY; Toi M; Carbone D; Geoerger B; Serra V; Jones RH; Ngeow J; Toska E; Stebbing J; Crasta K; Finn RS; Diana P; Vuina K; de Bruin RAM; Surana U; Bardia A; Kumar AP
    Drug Resist Updat; 2024 Sep; 76():101103. PubMed ID: 38943828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
    Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
    Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer.
    De Angelis C; Fu X; Cataldo ML; Nardone A; Pereira R; Veeraraghavan J; Nanda S; Qin L; Sethunath V; Wang T; Hilsenbeck SG; Benelli M; Migliaccio I; Guarducci C; Malorni L; Litchfield LM; Liu J; Donaldson J; Selenica P; Brown DN; Weigelt B; Reis-Filho JS; Park BH; Hurvitz SA; Slamon DJ; Rimawi MF; Jansen VM; Jeselsohn R; Osborne CK; Schiff R
    Clin Cancer Res; 2021 Sep; 27(17):4870-4882. PubMed ID: 33536276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and Biological Evaluation of Novel
    Song X; Gan Q; Zhang X; Zhang J
    Mol Pharm; 2019 Oct; 16(10):4213-4222. PubMed ID: 31424939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer.
    Dang F; Nie L; Zhou J; Shimizu K; Chu C; Wu Z; Fassl A; Ke S; Wang Y; Zhang J; Zhang T; Tu Z; Inuzuka H; Sicinski P; Bass AJ; Wei W
    Nat Commun; 2021 Sep; 12(1):5386. PubMed ID: 34508104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
    Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
    Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer.
    Chen F; Liu C; Zhang J; Xu W; Zhang Y
    Anticancer Agents Med Chem; 2018; 18(9):1241-1251. PubMed ID: 28403773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders.
    Wu X; Yang X; Xiong Y; Li R; Ito T; Ahmed TA; Karoulia Z; Adamopoulos C; Wang H; Wang L; Xie L; Liu J; Ueberheide B; Aaronson SA; Chen X; Buchanan SG; Sellers WR; Jin J; Poulikakos PI
    Nat Cancer; 2021 Apr; 2(4):429-443. PubMed ID: 34568836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis of inhibition of CDK-cyclin complexes by INK4 inhibitors.
    Jeffrey PD; Tong L; Pavletich NP
    Genes Dev; 2000 Dec; 14(24):3115-25. PubMed ID: 11124804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.
    Wander SA; Cohen O; Gong X; Johnson GN; Buendia-Buendia JE; Lloyd MR; Kim D; Luo F; Mao P; Helvie K; Kowalski KJ; Nayar U; Waks AG; Parsons SH; Martinez R; Litchfield LM; Ye XS; Yu C; Jansen VM; Stille JR; Smith PS; Oakley GJ; Chu QS; Batist G; Hughes ME; Kremer JD; Garraway LA; Winer EP; Tolaney SM; Lin NU; Buchanan SG; Wagle N
    Cancer Discov; 2020 Aug; 10(8):1174-1193. PubMed ID: 32404308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4/6-dependent tumors and tissues.
    Ramsey MR; Krishnamurthy J; Pei XH; Torrice C; Lin W; Carrasco DR; Ligon KL; Xiong Y; Sharpless NE
    Cancer Res; 2007 May; 67(10):4732-41. PubMed ID: 17510401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
    Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
    Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A deep learning model of tumor cell architecture elucidates response and resistance to CDK4/6 inhibitors.
    Park S; Silva E; Singhal A; Kelly MR; Licon K; Panagiotou I; Fogg C; Fong S; Lee JJY; Zhao X; Bachelder R; Parker BA; Yeung KT; Ideker T
    Nat Cancer; 2024 Jul; 5(7):996-1009. PubMed ID: 38443662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. O-GlcNAcylation of MITF regulates its activity and CDK4/6 inhibitor resistance in breast cancer.
    Zhang Y; Zhou S; Kai Y; Zhang YQ; Peng C; Li Z; Mughal MJ; Julie B; Zheng X; Ma J; Ma CX; Shen M; Hall MD; Li S; Zhu W
    Nat Commun; 2024 Jul; 15(1):5597. PubMed ID: 38961064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDAC5 Loss Impairs RB Repression of Pro-Oncogenic Genes and Confers CDK4/6 Inhibitor Resistance in Cancer.
    Zhou Y; Jin X; Ma J; Ding D; Huang Z; Sheng H; Yan Y; Pan Y; Wei T; Wang L; Wu H; Huang H
    Cancer Res; 2021 Mar; 81(6):1486-1499. PubMed ID: 33419772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6.
    Jiang B; Wang ES; Donovan KA; Liang Y; Fischer ES; Zhang T; Gray NS
    Angew Chem Int Ed Engl; 2019 May; 58(19):6321-6326. PubMed ID: 30802347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.